Clicky

Astellas Pharma Inc(ALPMF)

Description: Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers XTANDI and Eligard for the treatment of prostate cancer; Betanis/Myrbetriq/BETMIGA for overactive bladder (OAB) treatment; Vesicare forOAB treatment; Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia; VESOMNI for storage symptoms and voiding symptoms associated with benign prostatic hyperplasia; Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, animmunosuppressant; and Funguard/MYCAMINE, a candin-type antifungal agent. It also provides Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Symbicort for the treatment for adult bronchial asthma and chronic obstructive pulmonary disease; Bonoteo for the treatment for osteoporosis; Suglat for the treatment of type 2 diabetes; and Repatha for the treatment of hypercholesterolemia. In addition, it offers Lexiscan, a pharmacologic stress agent; Tarceva, a treatment for non-small cell lung cancer; CRESEMBA, a azole antifungal; and Dificlir, a novel treatment for CDI. Additionally, it is developing enzalutamide, gilteritinib, enfortumab vedotin, zolbetuximab, roxadustat, and fezolinetant for oncology indications. The company has a collaboration with Actinium Pharmaceuticals, Inc. to apply Actinium warhead enabling technology platform for generating Actinium radio-conjugates with various Astellas targeting agents. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.


Keywords: Diabetes Organic Compounds Chemical Compounds Prostate Cancer Hypertension Asthma Non Small Cell Lung Cancer Lung Cancer Osteoporosis Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Cholesterol Pulmonary Disease Benign Prostatic Hyperplasia Hypercholesterolemia Sterol Lactams Small Cell Treatment Of Prostate Cancer Mitsubishi Ufj Financial Group Fortum Overactive Bladder Hyperplasia Type 2 Diabetes Bronchial Asthma Cdi Ceva Exports Pharmaceutical Products Roxadustat Tamsulosin Enzalutamide Gilteritinib Prograf Adult Bronchial Asthma Treatment For Hypertension Treatment For Non Small Cell Lung Cancer Treatment For Osteoporosis

Home Page: www.astellas.com

2-5-1, Nihonbashi-Honcho
Tokyo, 103-8411
Japan
Phone: 81 3 3244 3000


Officers

Name Title
Mr. Kenji Yasukawa Ph.D. Pres, CEO & Chairman
Mr. Naoki Okamura BSc Exec. VP, Chief Strategy Officer & Representative Director
Minoru Kikuoka CFO & Sr. Managing Exec. Officer
Nobue Yasuda Gen. Mang. of Fin. & Accounting Department
Mr. Yoshitsugu Shitaka Ph.D. Chief Scientific Officer & Sr. Managing Exec. Officer
Ms. Catherine B. Levitt Gen. Counsel
Mr. Katsuyoshi Sugita Chief People Officer and Chief Ethics & Compliance Officer
Mr. Stig Ogata VP of Corp. Communications
Ms. Collette Taylor Sr. VP of HR
Chihiro Yokota Sr. Corp. Exec. and Head of Japan/Asia Devel., Devel.

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 15.3139
Trailing PE: 23.5082
Price-to-Book MRQ: 2.3776
Price-to-Sales TTM: 0.0208
IPO Date:
Fiscal Year End: March
Full Time Employees: 14522
Back to stocks